MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.13986

Медицинская библиотека · European journal of haematology · 2023

Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.

Heftdal Line Dam, Hamm Sebastian Rask, Pérez-Alós Laura, Madsen Johannes Roth, Armenteros Jose Juan Almagro, Fogh Kamille, Kronborg Christoffer Cronwald, Vallentin Anders Pommer, Hasselbalch Rasmus Bo, Møller Dina Leth, Hansen Cecilie Bo, Pries-Heje Mia, Gang Anne Ortved, Ostrowski Sisse Rye, Frikke-Schmidt Ruth, Sørensen Erik, Hilsted Linda, Bundgaard Henning, Iversen Kasper, Garred Peter, Nielsen Susanne Dam, Grønbaek Kirsten

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination.

METHODS

In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon-γ release at 12 months.

RESULTS

In patients with lymphoid malignancies, SARS-CoV-2 receptor-binding domain IgG concentration and mean neutralizing capacity was lower than in controls at all time points. A diagnosis of chronic lymphocytic B-cell leukemia (CLL) or lymphoma was associated with humoral nonresponse at 12 months compared to having multiple myeloma/amyloidosis (p < .001 and p = .013). Compared to controls, patients with lymphoid malignancies had increased risk of cellular nonresponse. A lymphoma diagnosis was associated with lower risk of cellular nonresponse compared to patients with multiple myeloma/amyloidosis, while patients with CLL had comparable response rates to patients with multiple myeloma/amyloidosis (p = .037 and p = .280).

CONCLUSIONS

In conclusion, long-term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies.

Для цитирования: Heftdal Line Dam, Hamm Sebastian Rask, Pérez-Alós Laura, Madsen Johannes Roth, Armenteros Jose Juan Almagro, Fogh Kamille, Kronborg Christoffer Cronwald, Vallentin Anders Pommer, Hasselbalch Rasmus Bo, Møller Dina Leth, Hansen Cecilie Bo, Pries-Heje Mia, Gang Anne Ortved, Ostrowski Sisse Rye, Frikke-Schmidt Ruth, Sørensen Erik, Hilsted Linda, Bundgaard Henning, Iversen Kasper, Garred Peter, Nielsen Susanne Dam, Grønbaek Kirsten. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.. European journal of haematology. 2023. DOI: 10.1111/ejh.13986.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.